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Distinct Subtypes of Microparticle-containing Immune
Complexes Are Associated with Disease Activity,
Damage, and Carotid Intima-media Thickness in
Systemic Lupus Erythematosus
Paul R. Fortin, Nathalie Cloutier, Vincent Bissonnette, Ellie Aghdassi, Lihi Eder, 
David Simonyan, Nathalie Laflamme, and Eric Boilard
ABSTRACT. Objective. Microparticles (MP) are small extracellular vesicles present in body fluids. MP originate
from different cellular lineages, principally from platelets in blood, and may expose phosphatidylserine
(PS). In systemic lupus erythematosus (SLE), MP harbor immunoglobulin G (IgG), thereby forming
MP-containing immune complexes (mpIC). We aimed to verify an association between SLE disease
activity, damage, and surrogate markers of atherosclerosis and MP harboring IgG, taking into account
the platelet origin and PS exposure of MP.
Methods. MP expressing surface IgG, platelet antigen (CD41+), and PS were quantified using flow
cytometry in plasma of 191 women with SLE. Carotid ultrasounds (US) were available in 113 patients.
Spearman correlation analysis was used to analyze whether levels of MP were associated with the
following outcomes: SLE Disease Activity Index 2000 (SLEDAI-2K), Systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index (SDI), and carotid US
plaques and intima-media thickness (CIMT) as surrogates for vascular damage.
Results. We found CD41+ MP harboring IgG present in SLE. A positive correlation was found
between SLEDAI-2K and levels of CD41+ MP harboring IgG and exposing (p = 0.027) and
non-exposing PS (p = 0.001). Conversely, SDI (p = 0.024) and CIMT (p = 0.016) correlated with
concentrations of CD41– MP harboring IgG and exposing PS. Associations were independent of
low-density lipoprotein cholesterol level, body mass index, and antimalarial drug use.
Conclusion.Different subtypes of mpIC are produced in SLE and are associated with distinct clinical
characteristics such as disease activity and vascular damage. The assessment of MP subtypes might
serve for the design of predictive markers of disease activity and vascular damage in patients. 
(First Release September 1 2016; J Rheumatol 2016;43:2019–25; doi:10.3899/jrheum.160050)
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Microparticles (MP), also known as microvesicles, are small
extracellular vesicles with a diameter of 100–1000 nm
produced by cytoplasmic membrane budding and shedding.
MP are distinct from exosomes, which display smaller
dimensions (10–100 nm in diameter) and originate from a
pool of membranes in the multivesicular bodies1. Depending
on the cellular source and release trigger, MP consist of
different components, which originate from the surface and
intracellular compartments of the producing cell. Because
they can interact with other cells and can be internalized in
cell recipients, MP are thought to be involved in intercellular
communication1.
Cellular activation and apoptosis are triggers of MP
release. During this process, the membrane asymmetry is
generally lost because of major membrane and cytoskeleton
rearrangements, engaging exposition of anionic phospha-
tidylserine (PS) on MP surface2. PS can support coagulation
factor deposition, suggesting that PS-harboring MP may
participate in thrombosis3. Further, the recognition of PS by
developmental endothelial locus 1, lactadherin, or tyrosine
kinase receptors leads to rapid MP clearance from blood
circulation4,5,6. Although any cellular lineages might shed
MP, those from platelets and erythrocytes appear among the
most numerous in the blood of healthy individuals, the
platelet-derived MP alone representing the majority of
them7,8. Intriguingly, more than half of the platelet-derived
MP present in blood lack surface expression of PS, adding
an additional level to the heterogeneity of MP8,9.
Systemic lupus erythematosus (SLE) is an autoimmune
inflammatory disease with an important contribution of
immune complexes (IC). Deposition of pathogenic IC in
organs such as the kidneys and chronic inflammation all
contribute to tissue and vascular damage seen in patients with
SLE. In SLE, PS-positive MP expose autoantigens that are
recognized by autoantibodies, forming MP-containing IC
(mpIC)10,11,12. The cellular source of these antigenic MP is
unknown, although they seem to originate from apoptotic
bodies exposing nuclear antigens10. Because platelets do not
have a nucleus, they are generally not suspected to contribute
to the load of autoantigens hallmarked in SLE. However,
platelets represent a significant pool of autoantigens, such as
the non-histone nuclear protein high mobility group box 1
(HMGB1), which may be exposed by platelet MP13,14.
Further, platelets do have RNA, microRNA, and mitochon-
drial DNA, which are transferred from the megakaryocyte
during pro-platelet formation, and which could represent a
source of nucleic acid autoantigens15,16.
There is accumulating evidence pointing to an active
contribution of platelets to SLE pathology15. Hence, platelet
depletion in SLE-prone mice and the treatment of these mice
with the antagonist of the P2Y12 receptor clopidogrel (which
blocks platelet activation) results in reduced proteinuria,
kidney damage, and mortality17. In SLE, platelets display
surface activation markers. Increased levels of plate-
let-derived mediators such as soluble CD40 ligand,
P-selectin, and thromboxane have been consistently reported
in the blood of these patients15,18. Annexin V is a protein that
binds PS with high affinity. Because MP can expose PS,
annexin V-conjugated fluorescent probes are frequently used
to detect MP in biological fluids, such as plasma. In SLE,
annexin V-positive MP (annexin V+ MP) harbor immuno-
globulin G (IgG), forming annexin V+ mpIC. Of clinical
relevance, the levels of annexin V+ mpIC correlate with
concentrations of autoantibodies and complement activa-
tion10. Further, platelet MP are present at higher concentra-
tions in patients with SLE18. Whether MP of platelet origin
are antigenic in SLE, and whether platelet mpIC levels
correlate with clinical characteristics of SLE disease have not
been investigated. In our present study, our aims were to
determine whether platelet-derived MP harbored IgG and
whether we could detect associations between disease charac-
teristics and levels of MP subtypes in SLE.
MATERIALS AND METHODS
Patients. Blood was obtained from 191 consecutive women with SLE from
the University of Toronto Lupus Clinic between August 2010 and October
2011. Of these, 113 had a carotid ultrasound (US) performed. Those who
did not have carotid US either refused the extra research procedure or were
living too far away to come back for this test. All patients were women by
study design for 2 reasons: (1) to minimize the sex-specific variability in
cardiovascular (CV) risks and (2) to account for the sex disparity in SLE
because 90% of patients affected are women. Information on demographic
variables such as age (yrs), marital status (married/common law vs not),
education (completed high school or higher vs not), employment (working
vs not), race (white, Asian, black, or other), and menopausal status was
collected. In addition, data were collected on clinical variables including CV
risk factors [body mass index (BMI), smoking status (current, past, or never),
hypertension (Y/N), diabetes (Y/N), lupus disease duration (yrs)] and
selected current medication exposures [antimalarials (Y/N), antiplatelet or
anticoagulant (Y/N), lipid-lowering drugs (Y/N), or the use of prednisone
(average dose in mg/day)]. For control plasma samples, blood from 9
age-matched women was collected and processed using the same procedure
during the same period of time. This study has been reviewed and approved by
the Research Ethics Board of the University Health Network (#10-0637-BE)
and of the CHU de Québec – Université Laval (#B14-08-2108).
Preparation of plasma samples. Blood was collected from study participants
after 12-h to 14-h fasts in 4.5 ml citrate (0.109 M)-buffered glass tubes.
Blood was centrifuged at 1500 × g for 10 min at room temperature (RT), the
upper phase, poor in platelets, was separated, and centrifuged an additional
time at 1500 × g for 10 min at RT. The resulting plasma was immediately
conserved at –80°C in tube aliquots.
High-sensitivity flow cytometry. A FACS Canto II special order product
equipped with a small particle option was used for all our studies (BD
Biosciences)9. The variables used to detect small particles were close to
the optimal version described in Rousseau, et al19. Polystyrene micro-
spheres of defined dimensions were used to ensure that the instrument
settings between each experiment, and the lower and upper gate limits,
used 100-nm and 1000-nm diameter polystyrene microspheres, respec-
tively. Prior to the labeling of MP, plasma (5 µl) was incubated with 10
µM of thrombin inhibitor D-phenylalanyl-prolyl-arginyl chloromethyl
ketone (Sigma-Aldrich) for 10 min to inhibit coagulation induced by the
addition of 95-µl annexin V buffer (BD Biosciences), which contains
calcium. The plasma was then incubated with 0.75 µg of Alexa Fluor
647-conjugated F(ab’)2 goat anti-human IgG (Jackson ImmunoResearch),
0.5 µg of PE-conjugated mouse anti-human CD41 (M148; Abcam), and 3
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µl of V450-conjugated annexin V (BD Biosciences) in annexin V buffer for
30 min at RT prior to dilution with 400 µl of annexin V buffer. Three
different fluorescent probes were excited by 3 distinct lasers to avoid uncer-
tainties associated with fluorescence spillover. Quantification microspheres
(15 µm; Polysciences) were added to tubes immediately prior to cytofluo-
rometric analysis and were detected on basis of autofluorescence9,19. In these
experimental conditions, 97.06% ± 2 of the total CD41+ events (n = 191)
were included within the gate (MP gate; Supplementary Figure 1A, available
online at jrheum.org). Specificity of the MP labeling was verified in 50% of
the samples using isotypic antibodies and by the addition of 0.05% Triton
X100 (EMD Millipore), which dissolves membranes of MP, and 20 mM
EDTA (Fisher Scientific), which chelates calcium ions necessary for annexin
V binding (Supplementary Figure 1B, available online at jrheum.org).
Fluorescent-intact platelets that were generated by the addition of 1-µM cell
tracker CMFDA (5-chloromethylfluorescein diacetate; Invitrogen) to washed
platelets for 15 min following the manufacturer protocols19 were spiked in
SLE plasma to further ensure the distinction, on the basis of size and granu-
larity, of platelets and mpIC (Supplementary Figure 1C, available online at
jrheum.org).
Variables collected and measures of outcome. Four clinical outcome
variables with proven validity to measure SLE disease characteristics and
surrogate atherosclerotic vascular features were collected: (1) disease activity
was determined using the SLE Disease Activity Index 2000 (SLEDAI-2K)20,
(2) the Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SDI) was used to assess
cumulative and irreversible damage because of SLE21, and US of the carotids
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Figure 1. MP in patients with SLE are contained in immune complexes and form mpIC. A. Platelet MP contained in plasma from 1 representative patient with
SLE were labeled with PE-conjugated anti-human CD41 and fluorescent-positive signal was compared with background noise of the antibody left in PBS in
absence of plasma as negative control. B. MP in plasma from 1 healthy volunteer and 3 representative patients with SLE were labeled with PE-conjugated anti-
human CD41, V450-conjugated annexin V, and Alexa Fluor 647-conjugated anti-human IgG, demonstrating the presence of IgG on the surface of MP (mpIC).
CD41+ and CD41– populations contained in the MP gate were analyzed. The 4-quadrant gates were positioned according to the isotypic controls and EDTA
treatment (for annexin V labelings). The CD41–annexin V+ (blue), CD41+annexin V– (orange), and CD41+annexin V+ (green) mpIC are illustrated in flow
cytometric scatter graphs. MP not associated with IgG are presented; CD41–annexin V+ MP are shown in yellow and CD41+annexin V+ MP in purple. IgG+
population not associated with CD41+ or annexin V+ MP is shown in pink. C. Quantification of the CD41–annexin V+ (left), CD41+annexin V+ (middle), and
CD41+annexin V– (right) mpIC in plasma of healthy volunteers (n = 9) and patients with SLE (n = 191) are presented on graphs. MP: microparticles; SLE:
systemic lupus erythematosus; mpIC: MP-containing immune complexes; PE: phycoerythrin; PBS: phosphate buffered saline; IgG: immunoglobulin G.
allowed for the characterization of (3) the carotid intima-media thickness
(CIMT) and (4) the carotid plaque area (CPA). CIMT was obtained following
a standardized, reliable, validated method developed by Lonn, et al that is used
to assess the global extent of atherosclerosis in patients22,23,24. CPA from 2-
dimensional US images was measured using a previously described method25
using a high-resolution duplex US scanner (MyLabTMFive). Intraobserver
reliability (intraclass correlation) for this procedure was 0.94 for repeated
measurements26. US measurements were analyzed using the Image-Pro V4.5.1
software by an independent certified reader blinded to our study.
Statistical analyses. In the descriptive part of our analysis, the median with
interquartile range (IQR) were presented for continuous data, and frequency
and percentage for categorical data. Normality of continuous data was
rejected using Shapiro-Wilks test (not shown). The concentrations of the 3
subtypes of mpIC examined (CD41+ annexin V+ mpIC, CD41+ annexin 
V– mpIC, and  CD41– annexin V+ mpIC) were determined and then corre-
lations with SLEDAI-2K, SDI, CIMT, and CPA were estimated using
Spearman correlation coefficients. Partial Spearman correlations were used
to obtain the correlation coefficients adjusted for low-density lipoprotein
cholesterol (LDL-C), BMI, and antimalarial drug use. Fisher’s z transfor-
mation was used to estimate 95% CI for Spearman correlation coefficients.
SAS 9.3 software was used for all statistical analyses. All the presented data
on MP measurements were rounded to 2 digits to comply with the inherent
instrument precision.
RESULTS
We verified whether platelet-derived MP, recognized by the
expression of platelet antigen CD41 (CD41+), could also
harbor IgG in patients with SLE (Table 1), forming CD41+
mpIC. Because an important proportion of the platelet MP in
blood does not express surface PS7,8, the CD41+ annexin 
V– mpIC were also considered. Using high-sensitivity flow
cytometry to distinguish MP subtypes, we found that the
median (IQR) concentration in the plasma of patients with
SLE for CD41+ annexin V+ mpIC was 130/num/μl (40–400),
and 100/num/μl (20–1000) for CD41+ annexin V– mpIC.
Significant levels of CD41– annexin V+ mpIC were also
measured (400/num/μl, 200–900), pointing to the potential
contribution of other cellular lineages to the production of
MP in SLE (Figures 1A and 1B). Using a limited number of
age- and sex-matched healthy controls for comparison (n =
9), we found that the CD41+ annexin V+ mpIC and CD41+
annexin V– mpIC were essentially absent in healthy
individuals, while the induction of CD41– annexin V+ mpIC
in SLE appeared more modest (Figure 1C).
Thus, we verified whether the levels of the 3 MP subtypes
correlated with disease features. Results show a positive
correlation between the SLEDAI and CD41+ annexin 
V– mpIC (p = 0.001), and also with CD41+ annexin V+
mpIC (p = 0.027). Further, whereas no correlations were
observed between all types of mpIC and CPA, we observed
that the concentrations of CD41– annexin V+ mpIC in SLE
correlate positively with the SDI (p = 0.024) and CIMT (p =
0.0156; Table 2). These observations suggest different impli-
cations for MP of different cellular origins in the etiology and
clinical progression of SLE. Associations were independent
of LDL-C level, BMI, and antimalarial drug use (Table 2),
and these variables had no effect on calculated disease
outcome, including SDI (data not shown).
DISCUSSION
Reduced clearance of autoantigens, mostly DNA, RNA, and
nuclear components, is thought to contribute to the formation
2022 The Journal of Rheumatology 2016; 43:11; doi:10.3899/jrheum.160050
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Table 1. Patient characteristics. Values are n (%) or median (interquartile
range).
Characteristics Women with Patients with Carotid
SLE, n = 191 Ultrasound, n = 113
Demographics
Age, yrs 48.6 (34.8–57.4) 50.6 (39.6–59.5)
Marital status, married/common law 106 (55) 63 (56)
Education, completed college 
or higher 133 (70) 78 (69)
Employment, working 78 (41) 37 (33)
Race
White 109 (57) 66 (58)
Asian 39 (20) 25 (22)
Black 33 (17) 18 (16)
Other 10 (6) 4 (4)
Menopausal status, post-menopausal 105 (55) 71 (63)
BMI, kg/m2
Obese, BMI ≥ 30 33 (17) 19 (17)
Overweight, BMI ≥ 25 to < 30 47 (25) 27 (24)
Normal, BMI ≥ 18.5 to < 25 100 (52) 60 (53)
Underweight, BMI < 18.5 11 (6) 7 (6)
Smoking 
Current 18 (9) 8 (7)
Past 43 (23) 28 (25)
Never 130 (68) 77 (68)
Hypertension 57 (30) 35 (31)
Diabetes mellitus 6 (3) 6 (5)
LDL-C, mmol/l 2.36 (1.95–2.78) 2.20 (1.89–2.63)
Medication use
Antimalarial drugs 142 (74) 79 (70)
Antiplatelet or anticoagulant    48 (25) 34 (30)
Lipid-lowering drug 29 (15) 25 (22)
Prednisone 85 (45) 49 (43)
Average dose, mg/day 5 (5–10) 5 (5–10) 
Disease characteristics
Disease duration, yrs 16.0 (9.1–25.2) 16.3 (9.2–26.3)
Disease activity by SLEDAI score 2.0 (0–4.0) 2.0 (0–4.0)
Disease damage by SDI score 1.0 (0–2.0) 1.0 (0–3.0)
Vascular damage characteristics
CIMT, mm — 593 (543–678)
Total CPA, mm2 — 0 (0–0.08)
Concentration of mpIC subtypes
Total annexin V+ mpIC, 
num/μl 600 (300–1400) 600 (300–1500)
CD41+ annexin V+ mpIC, 
num/μl 130 (40–400) 120 (40–400)
CD41+ annexin V– mpIC, 
num/μl 100 (20–1000) 100 (20–1100)
CD41–  annexin V+ mpIC, 
num/μl 400 (200–900) 400 (200–1000)
SLE: systemic lupus erythematosus; BMI: body mass index; LDL-C:
low-density lipoprotein cholesterol; SLEDAI: Systemic Lupus Erythe-
matosus Disease Activity Index; SDI: Systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index;
CIMT: carotid intima-media thickness; CPA: carotid plaque area; mpIC:
microparticle-containing immune complexes.
of IC in SLE. Because IC appear pathogenic, the identifi-
cation of the source of autoantigens is clinically important.
Because the MP cargo is vast and consists of cytokines,
enzymes, immune receptors, and even organelles, mpIC can
represent highly potent mediators of autoimmunity. The
identification of markers associated with mpIC may unveil
cellular sources of autoantigens and molecular mechanisms
relevant to SLE pathogenesis.
It was suggested that MP, more particularly those derived
from apoptotic bodies and containing nuclear proteins and
that may be identified in our CD41– MP subpopulation, could
convey autoantigens, thereby providing a platform for the
formation of pathogenic IC. Thus we also assessed
non-platelet–derived mpIC  in our study. Vascular damage,
as assessed using CIMT in patients with SLE, correlated with
the concentrations of annexin V+ mpIC, which do not express
platelet marker CD41. The source of these MP remains to be
identified, but it could be the nucleated cells such as leuko-
cytes or endothelial cells, which lack surface CD41 and are
reportedly shown to actively produce MP in patients with
SLE27. Because they express surface PS, this subtype of
mpIC may also contribute to thrombosis and thereby increase
the risk of CV disease seen in patients with SLE. Intriguingly,
no correlations were observed with total plaque area.
Although it might be too early at this stage of our research to
identify the exact reason for this apparent discrepancy, we
suggest that changes to CIMT might be occurring earlier than
total plaque area in the development of the SLE disease, and
thus might be more efficiently detected and associated with
the identified mpIC subtype (annexin V+ CD41– mpIC) in
our clinical conditions. In SLE, the mechanism for arterial
thickening of the intima-media, rather than a primarily plaque
cholesterol-driven deposition, might thus associate with
involvement of mpIC. Further studies will certainly provide
the complete identification of this MP subtype and could
eventually serve as the design of predictive markers of
vascular damage in patients, perhaps when used in combi-
nation with other markers used in algorithms.
Although exploratory and in need of replication, we reveal
in our study that platelets, even though anucleated, represent
an important source of MP implicated in the formation of
mpIC in SLE. Proteins (e.g., HMGB1)13,14, and even nucleic
acids, are among the different autoantigens potentially
conveyed by platelet-derived MP and contributing to the
formation of CD41+ mpIC. Recognition of molecules present
on platelet MP by autoantibodies may also be because of
cross-reactivity. Hence, it was reported that the anti-dsDNA
antibodies that prevail in SLE, in fact, recognize platelet
glycoprotein IIIa (CD61), thus providing an additional expla-
nation for the high concentrations of platelet mpIC in
SLE28,29.
There is accumulating evidence pointing to MP as a source
of antigens in rheumatic diseases. In rheumatoid arthritis,
platelet MP in the synovial fluid harbor citrullinated
autoantigens (e.g., fibrinogen and vimentin) and form mpIC9.
In a seminal study that implicated 68 patients with SLE, other
investigators had confirmed the presence of IgG on the
surface of annexin V+ MP. Consistent with our findings, no
correlations were found between annexin V+ mpIC and the
SLEDAI10. Of importance, our study demonstrates that levels
2023Fortin, et al: Microparticles in SLE
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Table 2. Spearman correlation analyses of the microparticle subtype levels and SLE outcomes.
SLE Outcomes Microparticle Crude Spearman Correlation Partial Spearman Correlation, 
Subtype 3 Partial Variables: LDL-C, BMI, 
and Antimalarial Drugs
n r 95% CI p n r 95% CI p
SLEDAI-2K Total annexin V+ mpIC 191 0.12 –0.02 to 0.26 0.1026 179 0.15 0–0.29 0.0498
SLEDAI-2K CD41– annexin V+ mpIC 191 0.00 –0.14 to 0.14 0.9808 179 0.03 –0.12 to 0.17 0.7321
SLEDAI-2K CD41+ annexin V+ mpIC 191 0.16 0.02–0.30 0.0266 179 0.21 0.06–0.34 0.0058
SLEDAI-2K CD41+ annexin V– mpIC 191 0.23 0.09–0.36 0.0013 179 0.28 0.14–0.41 0.0002
SDI Total annexin V+ mpIC 191 0.13 –0.01 to 0.27 0.0635 179 0.14 –0.01 to 0.28 0.0625
SDI CD41– annexin V+ mpIC 191 0.16 0.02–0.30 0.0236 179 0.18 0.03–0.32 0.0181
SDI CD41+ annexin V+ mpIC 191 0.08 –0.06 to 0.22 0.2596 179 0.08 –0.07 to 0.22 0.3042
SDI CD41+ annexin V– mpIC 191 –0.12 –0.26 to 0.02 0.0891 179 –0.14 –0.28 to 0.01 0.0675
CIMT Total annexin V+ mpIC 113 0.21 0.03–0.38 0.0253 106 0.21 0.01–0.38 0.0364
CIMT CD41– annexin V+ mpIC 113 0.23 0.04–0.39 0.0156 106 0.21 0.02–0.39 0.0292
CIMT CD41+ annexin V+ mpIC 113 0.14 –0.05 to 0.32 0.1370 106 0.12 –0.08 to 0.31 0.2304
CIMT CD41+ annexin V– mpIC 113 0.03 –0.15 to 0.22 0.7236 106 0.06 –0.14 to 0.25 0.5739
CPA Total annexin V+ mpIC 113 0.01 –0.18 to 0.19 0.9384 106 –0.02 –0.22 to 0.17 0.8032
CPA CD41– annexin V+ mpIC 113 0.04 –0.14 to 0.23 0.6412 106 0.01 –0.19 to 0.2 0.9410
CPA CD41+ annexin V+ mpIC 113 –0.01 –0.19 to 0.18 0.9191 106 –0.05 –0.24 to 0.14 0.6082
CPA CD41+ annexin V– mpIC 113 –0.03 –0.22 to 0.15 0.7326 106 –0.07 –0.26 to 0.12 0.4546
Significant data are in bold face. SLE: systemic lupus erythematosus; LDL-C: low-density lipoprotein cholesterol; BMI: body mass index; SLEDAI-2K:
Systemic Lupus Erythematosus Disease Activity Index 2000; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology
Damage Index; CIMT: carotid intima-media thickness; CPA: carotid plaque area; mpIC: microparticle-containing immune complexes.
of platelet mpIC correlate with disease activity. These results
are surprising, considering that it most specifically implied
the annexin V– platelet mpIC, and that only more modest
correlations were observed between the extensive set of
clinical features examined and annexin V+ platelet mpIC.
Since PS exposure mediates MP clearance, we propose that
PS-negative platelet mpIC, which might be preferentially
produced during elevated disease activity and may not be
cleared sufficiently rapidly, might act as a source of
autoantigens, and could stealthily circulate in blood for a
longer period of time. How platelet MP maintain membrane
asymmetry is not clear at the moment. Unique activation
processes, the hydrolysis of surface PS by secreted phospho-
lipase A2 present in the plasma, or presence of enzymes
packaged within MP and capable of maintaining asymmetry,
all could explain the absence of PS on this subset of MP19.
While these observations reinforce the notion of MP hetero-
geneity, they also support the notion of platelet contribution
to SLE.
It was suggested that the blockade of MP surface
autoantigens might represent an attractive treatment strategy
in SLE30. However, in health, the function(s) of MP as small
autoantigen conveyers is unclear. They might serve to the
maintenance of homeostatic levels of autoantibodies and to
their elimination. Although lower concentrations of mpIC
were determined in healthy controls, a finding consistent with
studies from other groups10,11,12, the rather low number of
controls examined and potentially the lesser cell activation
in the absence of SLE might explain these observations.
Examination of larger patient cohorts, ideally with a broader
disease activity, and the inclusion of more control volunteers
will be required for future investigations.
Although MP have long been identified, the more recent
development of improved methodologies permitting their
detection and quantification has enhanced the recognition of
distinct subtypes of MP in pathologies. Taken together, our
observations suggest that potent biomarkers could be
unveiled through the appreciation of the heterogeneity of MP.
Future studies of microparticle-based biomarkers are
therefore necessary to determine whether clinical decisions
might be based according to their measurements.
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